Vivus Inc. Submits SEC Filing Regarding Pharmaceutical Preparations

Strategic Insights -

Vivus Inc., a pharmaceutical company, has submitted a Form 4 filing to the U.S. Securities and Exchange Commission (SEC) as required by law. The filing, dated May 29, 2015, discloses changes in ownership and transactions involving the company's equity securities. As a publicly-traded company, Vivus Inc. is subject to SEC regulations, which require the submission of specific financial information and statements. The company's SIC code is 2834, indicating that it operates in the pharmaceutical preparations industry.

Key Takeaways:

  • Vivus Inc. submitted a Form 4 filing to the SEC on May 29, 2015, disclosing changes in ownership and transactions involving equity securities.
  • The filing is a requirement for publicly-traded companies, as per SEC regulations, and provides financial information and statements.
  • The company's SIC code is 2834, indicating that it operates in the pharmaceutical preparations industry.
  • Vivus Inc. is required to submit periodic financial statements and updates to the SEC, including Form 3 for initial filings and Form 5 for annual statements of beneficial ownership.
  • The SEC filing contains information on the reporting person's relationship to Vivus Inc. and on purchases and sales of equity securities.
  • The forms contain detailed information on Vivus Inc.'s financial transactions and ownership, providing transparency and accountability to investors and stakeholders.

Statistics:

  • Date of SEC filing: May 29, 2015
  • SIC code: 2834 (Pharmaceutical Preparations)
  • SEC file number: 0001104659-15-042152
  • Contact information for Vivus Inc.: 351 E. EVELYN AVENUE, MOUNTAIN VIEW CA 94041, 6509345200
  • Company SIC code: 2834 pharmaceutical preparations
  • Form 4: Used for director, officer, and owner of more than 10% of a class of equity securities to file a statement of ownership.

Sources:

  • NewsRx journalists
  • U.S. Securities and Exchange Commission (SEC) filing (Form 4)
  • SEC website for additional information on this filing: http://www.sec.gov/Archives/edgar/data/1230057/0001104659-15-042152-index.html